PTO/SB/21 (09-04)

33,523

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/737,350-Conf. #6000 **TRANSMITTAL** Filing Date December 15, 2003 First Named Inventor **FORM** Elias GEORGES Art Unit 1641 (to be used for all correspondence after initial filing) **Examiner Name** Not Yet Assigned Attorney Docket Number Total Number of Pages in This Submission 3 AUR-011US/112418.149US2 ENCLOSURES (Check all that apply) After Allowance Communication Fee Transmittal Form Drawing(s) Appeal Communication to Board of Fee Attached Licensing-related Papers Appeals and Interferences Appeal Communication to TC Amendment/Reply Petition (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information Provisional Application Power of Attorney, Revocation Affidavits/declaration(s) Status Letter Change of Correspondence Address Other Enclosure(s) (please X Other Endocated Identify below): Extension of Time Request Terminal Disclaimer References as Cited (5) **Express Abandonment Request** Request for Refund x Information Disclosure Statement CD, Number of CD(s) Certified Copy of Priority Landscape Table on CD Document(s) Reply to Missing Parts/ Remarks Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name WILMER CUTLER PICKERING HALE AND DORR LLP Signature Printed name Ann-Louise Kerner, Ph.D. Date Reg. No.

I hereby certify that this correspondence	is being deposited with the U.S. Postal Service wit	h sufficient postage as First Class Mail, in
an envelope addressed to: Commission	ner for Patents, P.O Box 1450, Alexandria, VA 223	13-1450, on the date shown below.
		The Free of the Branch Control of the Control of th
Dated: October 5, 2005	Signature: Jarah Jaris	(Sarah Farris)
	Oignature:	(Galair Fairis)

October 5, 2005

OCT 07 2005

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Nated: October 5, 2005

lature: (1)(VWV)

Docket Nos.: AUR-011US and

112418.149US2

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Elias GEORGES et al.

Application No.: 10/737,350

Filed: December 15, 2003

For: HSC70 DIRECTED DIAGNOSTICS AND THERAPEUTICS FOR MULTIDRUG

RESISTANT NEOPLASTIC DISEASE

Confirmation No.: 6000

Art Unit: 1641

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

This Information Disclosure Statement is being filed prior to the mailing date of a first Office Action on the merits. No fee is required.

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.

Dated: October 5, 2005

Respectfully submitted,

Ann-Louise Kerner, Ph.D. Registration No.: 33,523

WILMER CUTLER PICKERING HALE AND

DORR LLP 60 State Street

Boston, Massachusetts 02109

(617) 526-6000

Attorney for Applicant

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

o respond to a collection of information unless it contains a valid OMB control number.				
Complete if Known				
Application Number	10/737,350			
Filing Date	December 15, 2003			
First Named Inventor	GEORGES et al.			
Art Unit	1641			
Examiner Name	Not Yet Assigned			
Attorney Docket Number	AUR-011US /112418.149US2			

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-4,444,744	04-24-1984	Goldenberg, Milton	
	AB*	US-5,762,930	06-09-1998	Fanger et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	* magazine journal corial cumposium catalog etc.) data paga(s) volume jacus number(s) pub		T²		
	CA	BICHART et al. Cytoskeletion alteration in MCF7R, a multidrug resistant human breast cancer cell line., <i>Anticancer Res.</i> , 1997, pp. 3393-401, Vol. 17.			
	СВ	ESSA et al. Vimentin expression in different types of breast carinom aimmunohistochemical study, <i>J. Egypt Soc. Parasitol.</i> , 1996, pp. 433-42, Vol. 26.			
	CC	HEIDENTHAL et al. The Binding in Vitro of Modified LDL to the Intermediate Filament Protein Vimentin, <i>Biochemical and Biophysical Research Communications</i> , 2000, pp. 49-53, Vol. 267.			
	CD	MESCHINI et al. Intracellular P-Glycoprotein Expression is Associated with the Intrinsic Multidrug Resistance Phenotype in Human Colon Adenocarcinoma Cells. <i>Int. J. Cancer</i> , (2000), pp. 615-628, Vol. 87.			
	CE	THOMAS et al., Association between Keratin and Vimentin Expression, Malignant Phenotype and Survival in Postmenopausal Breast Cancer Patients, Oct. 1999, pp. 2698-2703, Vol. 5.			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	<u> </u>	
Signature	Considered		

Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.